Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR)

Historical Holders from Q4 2015 to Q3 2025

Symbol: VYGR on Nasdaq
Type / Class: Equity / Common Stock, $0.001 par value
Shares outstanding: 55,482,166
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 30,211,020
Holdings value: $141,111,218
% of all portfolios: 0%
Number of holders: 114
Number of buys: 51
Number of sells: -56
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
ARMISTICE CAPITAL, LLC	7.57%	-22.8%	$19,614,000	-$5,772,120	4,200,000	-22.7%	Armistice Capital, LLC	30 Sep 2025
EcoR1 Capital, LLC	6.8%		$18,696,980		4,003,636		EcoR1 Capital, LLC	30 Sep 2025
BlackRock, Inc.	6.4%		$12,445,128		3,525,532		BlackRock, Inc.	31 Mar 2025

Institutional Holders of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	30,211,020	$141,111,218	-$12,466,237	$75,654	$563,669	$4.67	114
2025 Q2	33,174,673	$103,118,305	-$5,022,778	$70,597	$102,319	$3.11	107
2025 Q1	34,693,910	$117,319,204	-$2,380,756	$127,426	$43,602	$3.38	114
2024 Q4	34,577,603	$195,996,497	-$3,226,096	$342,468	$34,020	$5.67	130
2024 Q3	35,034,671	$205,128,146	-$20,241,650	$202,410	$232,245	$5.85	126
2024 Q2	38,132,801	$301,619,686	+$18,919,346	$286,342	$379,680	$7.91	126
2024 Q1	35,559,200	$331,104,508	+$80,441,114	$586,530	$328,643	$9.31	132
2023 Q4	26,951,934	$227,544,384	-$3,558,359	$188,212	$375,580	$8.44	107
2023 Q3	27,251,321	$211,188,846	+$537,246	$553,350	$344,875	$7.75	111
2023 Q2	26,875,646	$307,720,979	+$48,627,840	$421,360	$827,835	$11.45	106
2023 Q1	23,842,811	$183,821,375	-$454,983	$1,360,044	$946,017	$7.71	82
2022 Q4	23,994,562	$146,245,078	-$700,357	$7,320	$506,910	$6.10	69
2022 Q3	24,135,758	$142,907,865	+$347,568	$334,000	$1,361,000	$5.92	67
2022 Q2	24,076,804	$142,325,318	+$7,681,335	$418,000	$1,343,000	$5.91	74
2022 Q1	22,468,342	$171,312,566	+$28,627,560	$893,000	$3,351,000	$7.62	67
2021 Q4	18,846,543	$51,240,128	-$8,744,189	$353,000	$743,000	$2.71	52
2021 Q3	22,241,759	$58,623,539	-$4,030,195	$109,000	$190,000	$2.63	63
2021 Q2	23,442,885	$96,817,913	-$15,060,885	$739,000	$632,000	$4.13	72
2021 Q1	26,694,047	$125,738,812	-$5,939,201	$1,590,000	$240,000	$4.71	94
2020 Q4	27,690,758	$198,031,668	-$6,797,504	$1,681,000	$127,000	$7.15	95
2020 Q3	28,071,762	$299,694,014	-$21,155,353		$290,000	$10.67	107
2020 Q2	29,835,329	$376,668,426	-$3,115,117		$356,000	$12.62	108
2020 Q1	30,273,841	$276,907,152	-$8,724,603		$130,000	$9.15	116
2019 Q4	30,853,647	$429,835,458	-$4,780,916		$611,000	$13.95	134
2019 Q3	30,673,858	$527,882,858	+$3,530,435	$0	$1,182,000	$17.21	129
2019 Q2	29,288,476	$796,370,599	+$141,852,717	$890,000	$6,732,000	$27.22	124
2019 Q1	27,472,078	$525,823,405	+$8,007,882	$300,000	$1,530,000	$19.14	110
2018 Q4	27,858,099	$261,831,496	-$17,131,000	$0	$234,000	$9.40	114
2018 Q3	28,912,415	$547,055,271	-$4,047,273	$524,000	$623,000	$18.92	117
2018 Q2	29,099,816	$568,637,489	+$41,402,106	$664,000	$1,002,000	$19.54	124
2018 Q1	27,065,667	$508,508,214	+$36,985,561	$1,283,000	$678,000	$18.79	107
2017 Q4	25,186,321	$418,085,441	+$68,360,039	$1,106,000	$1,162,000	$16.60	98
2017 Q3	11,312,957	$232,911,475	+$24,126,972		$2,104,000	$20.59	74
2017 Q2	10,949,052	$98,104,354	-$1,702,259			$8.96	52
2017 Q1	11,060,819	$146,442,646	+$8,714,480			$13.24	46
2016 Q4	10,954,007	$139,545,784	+$4,079,335			$12.74	55
2016 Q3	10,637,831	$127,760,820	+$781,532			$12.01	50
2016 Q2	10,598,201	$116,470,479	+$5,910,371			$10.99	48
2016 Q1	10,015,808	$86,972,821	-$3,380,554			$8.73	41
2015 Q4	10,403,150	$225,137,498	+$219,950,498			$21.90	35